within Pharmacolibrary.Drugs.ATC.P;

model P01CC01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 1.3333333333333333,
    adminDuration  = 600,
    adminMass      = 0.12,
    adminCount     = 1,
    Vd             = 0.089,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.007750000000000001,
    Tlag           = 12.0
  );

  annotation(Documentation(
    info ="<html><body><p>Nifurtimox is a nitrofuran derivative used primarily for the treatment of Chagas disease (American trypanosomiasis), caused by Trypanosoma cruzi. It has antiparasitic activity and is sometimes used off-label for other trypanosomal diseases. Nifurtimox has been approved for use in several countries, but is often reserved for cases where benznidazole is not available or appropriate.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adults after oral administration; data primarily from non-compartmental and compartmental PK studies.</p><h4>References</h4><ol><li><p>Schulz, SI, et al., &amp; Stass, H (2023). . <i>Current drug metabolism</i> 24(8) 599–610. DOI:<a href=&quot;https://doi.org/10.2174/1389200224666230817114758&quot;>10.2174/1389200224666230817114758</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37592798/&quot;>https://pubmed.ncbi.nlm.nih.gov/37592798</a></p></li><li><p>Lang, D, et al., &amp; Stass, H (2022). Structural and Mechanistic Investigation of the Unusual Metabolism of Nifurtimox. <i>Chemical research in toxicology</i> 35(11) 2037–2048. DOI:<a href=&quot;https://doi.org/10.1021/acs.chemrestox.2c00210&quot;>10.1021/acs.chemrestox.2c00210</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36209416/&quot;>https://pubmed.ncbi.nlm.nih.gov/36209416</a></p></li><li><p>Amilon, C, et al., &amp; Jansson-Löfmark, R (2022). Population Pharmacodynamic Modeling of Eflornithine-Based Treatments Against Late-Stage Gambiense Human African Trypanosomiasis and Efficacy Predictions of L-eflornithine-Based Therapy. <i>The AAPS journal</i> 24(3) 48–None. DOI:<a href=&quot;https://doi.org/10.1208/s12248-022-00693-2&quot;>10.1208/s12248-022-00693-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35338410/&quot;>https://pubmed.ncbi.nlm.nih.gov/35338410</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end P01CC01;
